BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas

Phase 1

Completed

Conditions: Stomach Neoplasms
Esophageal Neoplasms

Interventions: Drug: BMS-833923
Drug: Cisplatin
Drug: Capecitabine

First Posted Date: 2009-05-28

Last Posted Date: 2013-06-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 39

Registration Number: NCT00909402

Locations: 🇳🇱
Local Institution, Amsterdam, Netherlands
🇺🇸
City Of Hope National Medical Center, Duarte, California, United States
🇺🇸
Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 1 locations

Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: BMS-830216
Drug: Placebo

First Posted Date: 2009-05-28

Last Posted Date: 2015-11-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 113

Registration Number: NCT00909766

Locations: 🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States

Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC

Phase 3

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Brivanib
Other: Brivanib Placebo
Procedure: TACE Therapy

First Posted Date: 2009-05-27

Last Posted Date: 2019-12-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 734

Registration Number: NCT00908752

Locations: 🇺🇸
The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Sharp Clinical Oncology Research, San Diego, California, United States
🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States

and more 5 locations

Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Colorectal Cancer
Head and Neck Cancer
Neoplasm Metastasis

Interventions: Drug: BMS-754807
Drug: cetuximab (Erbitux®)

First Posted Date: 2009-05-25

Last Posted Date: 2013-06-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 54

Registration Number: NCT00908024

Locations: 🇺🇸
University Of Wisconsin, Madison, Wisconsin, United States
🇨🇦
Local Institution, Toronto, Ontario, Canada
🇺🇸
Nebraska Methodist Hospital, Omaha, Nebraska, United States

and more 1 locations

Drug-Drug Interaction Study in Healthy Subjects

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: BMS-790052
Drug: BMS-650032

First Posted Date: 2009-05-19

Last Posted Date: 2011-01-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 28

Registration Number: NCT00904059

Locations: 🇺🇸
Ppd Development, Lp, Austin, Texas, United States

Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease

Phase 1

Completed

Conditions: Alzheimer's Disease
Healthy

Interventions: Drug: BMS-708163

First Posted Date: 2009-05-13

Last Posted Date: 2011-01-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 36

Registration Number: NCT00901498

Locations: 🇺🇸
Mds Pharma Services (Us) Inc., Neptune, New Jersey, United States

A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster

Phase 2

Completed

Conditions: Shingles
Herpes Zoster

Interventions: Drug: FV-100
Drug: valacyclovir
Drug: Valacyclovir placebo
Drug: FV-100 placebo

First Posted Date: 2009-05-13

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 350

Registration Number: NCT00900783

Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BMS-754807

First Posted Date: 2009-05-12

Last Posted Date: 2011-11-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 15

Registration Number: NCT00898716

Locations: 🇯🇵
Local Institution, Chuo-Ku, Tokyo, Japan

Multiple-Ascending Dose Study

Phase 1

Completed

Conditions: Depression

Interventions: Drug: BMS-820836
Drug: Placebo

First Posted Date: 2009-05-05

Last Posted Date: 2011-02-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 57

Registration Number: NCT00892840

Locations: 🇸🇪
Local Institution, Uppsala, Sweden

A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease

Phase 2

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: Placebo
Drug: Avagacestat

First Posted Date: 2009-04-30

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 263

Registration Number: NCT00890890

Locations: 🇺🇸
Pivotal Research Centers, Peoria, Arizona, United States
🇺🇸
Nyu Langone Medical Center, New York, New York, United States
🇺🇸
Yale University School Of Medicine, New Haven, Connecticut, United States

and more 48 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy